phosphonoacetic acid has been researched along with Recrudescence in 15 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 9.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 9.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 6.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 5.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 5.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | 3.68 | Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "The herpesvirus DNA polymerase inhibitor foscarnet, applied topically, and the anti-herpesvirus guanosine analogue buciclovir, given orally, decreased virus replication and disease development in primary skin infections of mice caused by herpes simplex virus type 1 (HSV-1)." | 3.67 | Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. ( Datema, R; Ericson, AC; Kristofferson, A; Sohl-Akerlund, A, 1988) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| " No significant difference in the incidence of local or systemic adverse effects was noted between the two groups." | 2.66 | Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study. ( Aoki, FY; Lawee, D; Portnoy, J; Rosenthal, D, 1988) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 2.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | 2.36 | [Herpes simplex]. ( Fanta, D, 1981) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doyle, JA | 1 |
| Perry, HO | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Fanta, D | 1 |
| Jabs, DA | 1 |
| Birch, CJ | 1 |
| Tyssen, DP | 1 |
| Tachedjian, G | 1 |
| Doherty, R | 1 |
| Hayes, K | 1 |
| Mijch, A | 1 |
| Lucas, CR | 1 |
| Safrin, S | 1 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Davis, R | 1 |
| Hafner, R | 1 |
| Rush, J | 1 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| Mills, J | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 2 |
| Harris, JR | 2 |
| Pinching, AJ | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Arbesfeld, DM | 1 |
| Thomas, I | 1 |
| Walmsley, SL | 1 |
| Chew, E | 1 |
| Read, SE | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Rachlis, A | 1 |
| Fanning, MM | 1 |
| Kristofferson, A | 1 |
| Ericson, AC | 1 |
| Sohl-Akerlund, A | 1 |
| Datema, R | 1 |
| Barton, SE | 1 |
| Munday, PE | 1 |
| Kinghorn, GR | 1 |
| van der Meijden, WI | 1 |
| Stolz, E | 1 |
| Notowicz, A | 1 |
| Rashid, S | 1 |
| Schuller, JL | 1 |
| Essex-Cater, AJ | 1 |
| Kuijpers, MH | 1 |
| Sacks, SL | 1 |
| Portnoy, J | 2 |
| Lawee, D | 2 |
| Schlech, W | 1 |
| Aoki, FY | 2 |
| Tyrrell, DL | 1 |
| Poisson, M | 1 |
| Bright, C | 1 |
| Kaluski, J | 1 |
| Rosenthal, D | 1 |
| Wallin, J | 1 |
| Lernestedt, JO | 1 |
| Ogenstad, S | 1 |
| Lycke, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for phosphonoacetic acid and Recrudescence
| Article | Year |
|---|---|
[Herpes simplex].
Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe | 1981 |
Cutaneous herpes simplex virus infections.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Drug Resistance, Microbi | 1991 |
5 trials available for phosphonoacetic acid and Recrudescence
| Article | Year |
|---|---|
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
Topics: Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Female; Foscarnet; Herpes Ge | 1986 |
Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
Topics: Administration, Topical; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Double-Blind | 1987 |
Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Double | 1988 |
Topical treatment of recurrent genital herpes infections with foscarnet.
Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Erythema; Female; Fos | 1985 |
8 other studies available for phosphonoacetic acid and Recrudescence
| Article | Year |
|---|---|
Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Topics: Adult; Aged; Arthritis; Aspartic Acid; Diarrhea; Drug Eruptions; Female; Follow-Up Studies; Humans; | 1984 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C | 1992 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Foscarnet effective in acyclovir-resistant herpes.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1991 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Topics: Acyclovir; Administration, Oral; Administration, Topical; Animals; Antiviral Agents; Disease Models, | 1988 |